Skip to main content

Qualified laboratory research use only. Not for human or veterinary use, consumption, administration, compounding, diagnosis, or treatment.

RESEARCH USE ONLY

Technical research brief

BPC-157: Identity, Evidence, and Documentation

A source-backed research brief covering BPC-157 identity, model-system evidence, interpretation limits, and lot documentation.

4 min readPreclinical-dominant evidencePrimary sources linked

BPC-157 is cataloged here as a synthetic pentadecapeptide. BPC-157 is a 15-amino-acid research peptide. Published work has mostly used isolated cells, tissues, and animal models to study vascular signaling and repair-related processes.

Scope of this brief

This page separates molecular identity, published model-system observations, and procurement documentation. It is not a protocol and contains no instructions for administration or personal use.

Identity before interpretation

The short name “BPC-157” does not establish salt form, counter-ion, purity, or peptide-related impurities. Those details belong in a lot-specific specification or analytical record.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

  • Endothelial signaling and nitric-oxide-associated vascular responses in cell, tissue, and animal models.
  • VEGFR2-associated signaling, endothelial migration, and tube-formation assays.
  • How peptide identity, impurities, and experimental system affect reproducibility across studies.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

  • A 2017 study reported VEGFR2-associated effects in endothelial assays and a rat hind-limb ischemia model.
  • A 2026 ex vivo study used discarded human internal mammary artery rings; it was a tissue experiment, not a clinical safety or efficacy trial.
  • Model-specific findings should be described as observations in those systems, not as established outcomes in people or animals.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

  • The public literature does not establish this Vespera catalog material as safe, effective, sterile, or suitable for administration.
  • FDA identifies limited safety information and peptide-impurity and characterization concerns for compounded drugs containing BPC-157.
  • A research-use label is meaningful only when buyer qualification, access control, fulfillment review, and actual use remain research-only.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

  • Match the exact product name, selected strength, SKU, and lot or batch identifier.
  • Review the stated analytical method, result, sample identity, and report date together.
  • Do not treat a purity percentage alone as proof of sequence identity, quantity, sterility, or suitability for a particular experiment.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

  1. Liu et al. — VEGFR2 activation and up-regulation in BPC-157 models (2017)Endothelial assays, chick membrane assay, and rat model.
  2. Yildirim et al. — vasorelaxant effects in human arterial rings (2026)Ex vivo human tissue study; not a clinical trial.
  3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded drugs containing BPC-157.
Research-use boundary

This educational summary does not make the Vespera catalog item a drug, medicine, supplement, cosmetic, compounded preparation, or consumer product. It is not for human or veterinary use.